Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir in Japanese Transplant Recipients with CMV
NCT05137717Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2022
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of maribavir in cytomegalovirus infection (CMV), sponsored by Takeda. Primary endpoints: Percentage of Participants Who Achieved Confirmed Clearance of Plasma CMV Deoxyribose Nucleic Acid (DNA) at Week 8, Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs at Week 20 and 7 more. Started Jan 2022; status: completed.
02
Drugs
maribavir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05137717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137717.